3/30
05:07 pm
gctk
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights [TheStreet.com]
Neutral
Report
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights [TheStreet.com]
3/30
04:50 pm
gctk
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Low
Report
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
3/28
12:10 am
gctk
Microcap MedTech Moving on U.S. Clinical Milestone [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Microcap MedTech Moving on U.S. Clinical Milestone [Globe and Mail, The (Toronto, Canada)]
3/27
10:09 pm
gctk
Glucotrack to File for FDA Exemption Based on 2025 Milestones [Yahoo! Finance]
Medium
Report
Glucotrack to File for FDA Exemption Based on 2025 Milestones [Yahoo! Finance]
3/27
08:07 am
gctk
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones [Yahoo! Finance]
High
Report
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones [Yahoo! Finance]
3/27
08:01 am
gctk
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
High
Report
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
3/10
08:01 am
gctk
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit
Low
Report
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit
1/29
05:53 pm
gctk
Glucotrack Announces 3 New Patents to Monitor Blood Glucose [Yahoo! Finance]
High
Report
Glucotrack Announces 3 New Patents to Monitor Blood Glucose [Yahoo! Finance]
1/29
08:01 am
gctk
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
High
Report
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
12/30
08:00 am
gctk
Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor
High
Report
Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor